Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer.
about
Evolving Evidence of the Efficacy and Safety of nab-Paclitaxel in the Treatment of Cancers with Squamous HistologiesAlbumin-bound paclitaxel in solid tumors: clinical development and future directionsPromising targets and current clinical trials in metastatic squamous cell lung cancernab-paclitaxel for the management of patients with advanced non-small-cell lung cancer.Albumin-Bound Paclitaxel: A Review in Non-Small Cell Lung Cancer.Nab-Paclitaxel and Carboplatin (Nab-PC) Regimen for Advanced Non-Small-Cell Lung CancerTreatment of recurrent and platinum-refractory stage IV non-small cell lung cancer with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as a single agent.Stromal Caveolin-1 Is Associated With Response and Survival in a Phase II Trial of nab-Paclitaxel With Carboplatin for Advanced NSCLC Patients.First line treatment of advanced non-small-cell lung cancer - specific focus on albumin bound paclitaxel.Chemotherapy in Metastatic NSCLC - New Regimens (Pemetrexed, Nab-Paclitaxel)Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer.Rationale for targeting the ErbB family of receptors in patients with advanced squamous cell carcinoma of the lung.A randomized placebo-controlled clinical study of nab-paclitaxel as second-line chemotherapy for patients with advanced non-small cell lung cancer in ChinaA phase II open-label clinical study of comparing nab-paclitaxel with pemetrexed as second-line chemotherapy for patients with stage IIIB/IV non-small-cell lung cancer.Interstitial Lung Disease Following Single-Agent Nanoparticle Albumin-Bound Paclitaxel Treatment in Patients with Advanced Non-Small Cell Lung Cancer.A randomized phase II study of erlotinib plus nab-paclitaxel versus erlotinib alone as second-line therapy for Chinese patients with advanced EGFR wild-type non-small-cell lung cancer.A single-arm phase II study of nab-paclitaxel for patients with chemorefractory non-small cell lung cancerComparative effectiveness and safety of nab-paclitaxel plus carboplatin vs gemcitabine plus carboplatin in first-line treatment of advanced squamous cell non-small cell lung cancer in a US community oncology setting.Retrospective analysis of single-agent nab-paclitaxel in patients with platinum-resistant non-small cell lung cancer.A Phase I/II Study of Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Squamous Cell Cancer of the Head and Neck.Nab-paclitaxel as second-line treatment in advanced gastric cancer: a multicenter phase II study of the Hellenic Oncology Research Group.The Safety and Efficacy of Treatment with Nab-Paclitaxel and Carboplatin for Patients with Advanced Squamous Non-small Cell Lung Cancer Concurrent with Idiopathic Interstitial Pneumonias.A phase II clinical study of using nab-paclitaxel as second-line chemotherapy for Chinese patients with advanced non-small cell lung cancer.Assessing the clinical outcome of nab-paclitaxel in Chinese patients with advanced non-small-cell lung cancer.[Clinical Research on Albumin-bound Paclitaxel-based Therapy in Advanced Lung Cancer].Tetrandrine suppresses lung cancer growth and induces apoptosis, potentially via the VEGF/HIF-1α/ICAM-1 signaling pathway.nab-Paclitaxel/carboplatin in elderly patients with advanced squamous non-small cell lung cancer: a retrospective analysis of a Phase III trial.Efficacy and safety of weekly nab-paclitaxel plus cisplatin with concurrent intensity-modulated radiotherapy in patients with inoperable, locally advanced esophageal cancer: a pilot trial
P2860
Q26766254-BC840B36-C904-4C11-B1D3-2E6FB73125AEQ26798674-50911805-2004-4E06-9A1D-56B66FF656DDQ28083663-3655FDAB-7117-4FC3-8B2A-1C4E5B915850Q33412928-719D311F-57B6-49B9-8C06-4ECD96039942Q33427359-54B2D7D2-9F34-46F3-AC4C-70C98FFFD9BEQ34612764-98D01781-FE5E-4A4D-A543-1E85F2B7E78CQ37119741-7C54BB81-6B58-412F-A76D-26253655B67DQ37361227-41BDD549-42BE-4BFE-9EE7-52DADEB7DF56Q37419857-DE6470DE-9C61-4EC3-897B-C7CC65C0C246Q38237655-0E037543-2E82-4AC1-9BD0-30573B337024Q38258744-21EB7816-2BBE-458C-816B-39D117F60155Q38514601-04039679-CD0E-4066-95B7-AE3FFB8951E6Q41138923-22CE8DF9-FA84-452D-ACFA-8A49B7D3A9D1Q41591590-4D6D60F2-2C44-4DEB-801A-739BE26FC91CQ41601086-FE0E865C-F372-43A1-9EC5-48A4E247D2D5Q41755815-F396796C-2CC9-4EE0-A82D-2490B9120A4BQ42689822-29233151-4C2A-4666-938F-1C5D181F8E36Q47156167-17E0779F-F73F-4BBF-A425-9A037CCD21FBQ47205440-095A3D72-4C8C-44F1-B3BC-7FD66E1A0C89Q47253569-46D7A925-DD18-451D-8370-F9AC957672D8Q49657442-D94AB785-7B6B-4195-A918-DCC30134A922Q50046190-41F7DA9D-5654-45BD-838B-3B1F70B92444Q51027401-E2AC4BFC-BF7C-4292-AEAF-21CC9162A2F2Q51591928-C06EE139-0D49-46FD-9037-CD26FA8DB6F0Q53145703-C95B5CA4-4337-47FD-8BE1-2D300933A268Q54940276-D81023C3-DC93-4AA2-83ED-DC25BA67C746Q54962536-3E185CA9-F547-45E8-999D-4A0B80CCA9B4Q57490416-3FBD09B2-38C0-422A-AD4D-DC663413285C
P2860
Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Safety and efficacy analysis b ...... ed non-small-cell lung cancer.
@ast
Safety and efficacy analysis b ...... ed non-small-cell lung cancer.
@en
type
label
Safety and efficacy analysis b ...... ed non-small-cell lung cancer.
@ast
Safety and efficacy analysis b ...... ed non-small-cell lung cancer.
@en
prefLabel
Safety and efficacy analysis b ...... ed non-small-cell lung cancer.
@ast
Safety and efficacy analysis b ...... ed non-small-cell lung cancer.
@en
P2093
P2860
P356
P1433
P1476
Safety and efficacy analysis b ...... ed non-small-cell lung cancer.
@en
P2093
M A Socinski
M F Renschler
N Yamamoto
S R Dakhil
P2860
P304
P356
10.1093/ANNONC/MDT235
P577
2013-07-10T00:00:00Z